Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery

Gene Therapy

Volumn 11, Issue 17, 2004, Pages 1312-1320

  Kang, Q ^a,b   Sun, M H ^a   Cheng, H ^a   Peng, Y ^a,c   Montag, A G ^a,c   Deyrup, A T ^a,c,d   Jiang, W ^a   Luu, H H ^a   Luo, J ^a   Szatkowski, J P ^a   Vanichakarn, P ^a   Park, J Y ^a   Li, Y ^a   Haydon, R C ^a   He, T C ^a,c  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CHICAGO   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone formation; Bone morphogenetic protein; Bone regeneration; Osteoblast differentiation; Osteogenesis; Recombinant adenovirus

Indexed keywords

ADENOVIRUS VECTOR; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 9; GROWTH FACTOR; OSTEOGENIC PROTEIN 1; OSTEOGENIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; BMP2 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE RADIOGRAPHY; BONE REGENERATION; CONTROLLED STUDY; DRUG MECHANISM; HISTOLOGY; HUMAN; HUMAN CELL; MALE; MOUSE; MUSCULOSKELETAL DISEASE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUADRICEPS FEMORIS MUSCLE; REVIEW; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; ADENOVIRUS; ANIMAL; ARTICLE; BONE DEVELOPMENT; BONE DISEASE; CELL LINE; GENE THERAPY; GENE VECTOR; GENETICS; INTRAMUSCULAR DRUG ADMINISTRATION; METHODOLOGY; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOVIRIDAE; STAPHYLOCOCCUS PHAGE 3A;

ADENOVIRIDAE; ANIMALS; BONE DISEASES; BONE MORPHOGENETIC PROTEINS; CELL LINE; GENE THERAPY; GENETIC VECTORS; INJECTIONS, INTRAMUSCULAR; MALE; MICE; MICE, NUDE; OSTEOGENESIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 4444329294     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302298     Document Type: Review

References (81)

1. DeWitt N. Bone and cartilage. Nature 2003; 423: 315.
2. Olsen BR, Reginato AM, Wang W. Bone development. Annu Rev Cell Dev Biol 2000; 16: 191-220.
3. Reddi AH. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 1998; 16: 247-252.
4. Urist MR. Bone: formation by autoinduction. Science 1965; 150: 893-899.
5. Wozney JM et al. Novel regulators of bone formation: molecular clones and activities. Science 1988; 242: 1528-1534.
6. Hogan BL. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 1996; 10: 1580-1594.
7. Zou H et al. BMP signaling and vertebrate limb development. Cold Spring Harb Symp Quant Biol 1997; 62: 269-272.
8. Massague J, Weis-Garcia F. Serine/threonine kinase receptors: mediators of transforming growth factor beta family signals. Cancer Surv 1996; 27: 41-64.
9. Yamashita H, Ten Dijke P, Heldin CH, Miyazono K. Bone morphogenetic protein receptors. Bone 1996; 19: 569-574.
10. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-471.
11. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-791.
12. Wrana JL. Regulation of Smad activity Cell 2000; 100: 189-192.
13. Heckman JD, Boyan BD, Aufdemorte TB, Abbott JT. The use of bone morphogenetic protein in the treatment of non-union in a canine model. J Bone Joint Surg Am 1991; 73: 750-764.
14. Gerhart TN et al. Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. Clin Orthop 1993; 349: 317-326.
15. Lee SC et al. Healing of large segmental defects in rat femurs is aided by RhBMP-2 in PLGA matrix. J Biomed Mater Res 1994; 28: 1149-1156.
16. Bostrom MP, Camacho NP. Potential role of bone morphogenetic proteins in fracture healing. Clin Orthop 1998; 355 (Suppl): S274-S282.
17. Cheng SL et al. In vitro and in vivo induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene. Calcif Tissue Int 2001; 68: 87-94.
18. Krebsbach PH, Go K, Franceschi RT, Rutherford RB. Gene therapy-directed osteogenesis: BMP-7-transduced human fibroblasts form bone in vivo (in process citation). Hum Gene Ther 2000; 11: 1201-1210.
19. Partridge K et al. Adenoviral BMP-2 gene transfer in mesenchymal stem cells: in vitro and in vivo bone formation on biodegradable polymer scaffolds. Biochem Biophys Res Commun 2002; 292: 144-152.
20. Riew KD et al. Induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene in a rabbit spinal fusion model. Calcif Tissue Int 1998; 63: 357-360.
21. Varady P et al. Morphologic analysis of BMP-9 gene therapy-induced osteogenesis. Hum Gene Ther 2001; 12: 697-710.
22. Varady P et al. CT and radionuclide study of BMP-2 gene therapy-induced bone formation. Acad Radiol 2002; 9: 632-637.
23. Helm GA et al. Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. J Neurosurg 2000; 92: 191-196.
24. Sandhu HS, Khan SN, Suh DY, Boden SD. Demineralized bone matrix, bone morphogenetic proteins, and animal models of spine fusion: an overview. Eur Spine J 2001; 10 (Suppl. 2): S122-S131.
25. Boden SD, Zdeblick TA, Sandhu HS, Heim SE. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine 2000; 25: 376-381.
26. Friedlaender GE. OP-1 clinical studies. J Bone Joint Surg Am 2001; 83-A: S160-S161.
27. Valentin-Opran A et al. Clinical evaluation of recombinant human bone morphogenetic protein-2. Clin Orthop 2002; 395: 110-120.
28. Whang K et al. Ectopic bone formation via rhBMP-2 delivery from porous bioabsorbable polymer scaffolds. J Biomed Mater Res 1998; 42: 491-499.
29. Alden TD et al. Percutaneous spinal fusion using bone morphogenefic protein-2 gene therapy. J Neurosurg 1999; 90: 109-114.
30. Oyama M et al. Retrovirally transduced bone marrow stromal cells isolated from a mouse model of human osteogenesis imperfecta (oim) persist in bone and retain the ability to form cartilage and bone after extended passaging. Gene Therapy 1999; 6: 321-329.
31. Alden TD et al. In vivo endochondral bone formation using a bone morphogenetic protein 2 adenoviral vector. Hum Gene Ther 1999; 10: 2245-2253.
32. Baltzer AW et al. Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Therapy 2000; 7: 734-739.
33. Baltzer AW et al. Potential role of direct adenoviral gene transfer in enhancing fracture repair. Clin Orthop 2000; 379 (Suppl): S120-S125.
34. Bosch P et al. The efficiency of muscle-derived cell-mediated bone formation. Cell Transplant 2000; 9: 463-470.
35. Breitbart AS et al. Gene-enhanced tissue engineering: applications for bone healing using cultured periosteal cells transduced retrovirally with the BMP-7 gene. Ann Plast Surg 1999; 42: 488-495.
36. Franceschi RT, Wang D, Krebsbach PH, Rutherford RB. Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. J Cell Biochem 2000; 78: 476-486.
37. Gazit D et al. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. J Gene Med 1999; 1: 121-133.
38. Lieberman JR et al. Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 1998; 16: 330-339.
39. Lou J, Xu F, Merkel K, Manske P. Gene therapy: adenovirus-mediated human bone morphogenctic protein-2 gene transfer induces mesenchymal progenitor cell proliferation and differentiation in vitro and bone formation in vivo. J Orthop Res 1999; 17: 43-50.
40. Mason JM et al. Expression of human bone morphogenic protein 7 in primary rabbit periosteal cells: potential utility in gene therapy for osteochondral repair. Gene Therapy 1998; 5: 1098-1104.
41. Musgrave DS et al. Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone. Bone 1999; 24: 541-547.
42. Okubo Y et al. Osteoinduction by bone morphogenetic protein-2 via adenoviral vector under transient immunosuppression. Biochem Biophys Res Commun 2000; 267: 382-387.
43. Ripamonti U et al. Bone induction by BMPs/OPs and related family members in primates. J Bone Joint Surg Am 2001; 83-A: S116-S127.
44. Lee JY et al. Effect of bone morphogenetic protein-2-expressing muscle-derived cells on healing of critical-sized bone defects in mice. J Bone Joint Surg Am 2001; 83-A: 1032-1039.
45. Cheng H et al. Osteogenic activity of the 14 types of human bone morphogenetic proteins (BMPs). J Bone Joint Surgery Am 2003; 85-A: 1544-1552.
46. Robbins PD, Tahara H, Ghivizzani SC. Viral vectors for gene therapy. Trends Biotechnol 1998; 16: 35-40.
47. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
48. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727.
49. Breyer B et al. Adenoviral vector-mediated gene transfer for human gene therapy. Curr Gene Ther 2001; 1: 149-162.
50. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy Nat Rev Genet 2003; 4: 346-358.
51. Sun MH et al. Bone morphogenetic proteins and bone regeneration: from biology to clinical applications. Adv Osteoporotic Fract Manag 2003; 2: 70-78.
52. Bahamonde ME, Lyons KM. BMP3: to be or not to be a BMP. J Bone Joint Surg Am 2001; 83-A: S56-S62.
53. Lee JY et al. Enhancement of bone healing based on ex vivo gene therapy using human muscle-derived cells expressing bone morphogenetic protein 2. Hum Gene Ther 2002; 13: 1201-1211.
54. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 2002; 84-A: 1032-1044.
55. Noda M, Camilliere JJ. In vivo stimulation of bone formation by transforming growth factor-beta. Endocrinology 1989; 124: 2991-2994.
56. Joyce ME, Terek RM, Jingushi S, Bolander ME. Role of transforming growth factor-beta in fracture repair. Ann N Y Acad Sci 1990; 593: 107-123.
57. Lind M et al. Transforming growth factor-beta enhances fracture healing in rabbit tibiae. Acta Orthop Scand 1993; 64: 553-556.
58. Nielsen HM, Andreassen TT, Ledet T, Oxlund H. Local injection of TGF-beta increases the strength of fibial fractures in the rat. Acta Orthop Scand 1994; 65: 37-41.
59. Critchlow MA, Bland YS, Ashhurst DE. The effect of exogenous transforming growth factor-beta 2 on healing fractures in the rabbit. Bone 1995; 16: 521-527.
60. Sumner DR et al. Enhancement of bone ingrowth by transforming growth factor-beta. J Bone Joint Surg Am 1995; 77: 1135-1147.
61. Canalis E, Centrella M, McCarthy T. Effects of basic fibroblast growth factor on bone formation in vitro. J Clin Invest 1988; 81: 1572-1577.
62. Kato T et al. Single local injection of recombinant fibroblast growth factor-2 stimulates healing of segmental bone defects in rabbits. J Orthop Res 1998; 16: 654-659.
63. Nakamura T et al. Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture. J Bone Miner Res 1998; 13: 942-949.
64. Radomsky ML, Thompson AY, Spiro RC, Poser JW. Potential role of fibroblast growth factor in enhancement of fracture healing. Clin Orthop 1998; 355 (Suppl): S283-S293.
65. Radornsky ML et al. Novel formulation of fibroblast growth factor-2 in a hyaluronan gel accelerates fracture healing in nonhuman primates. J Orthop Res 1999; 17: 607-614.
66. Nash TJ et al. Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone 1994; 15: 203-208.
67. Thaller SR, Dart A, Tesluk H. The effects of insulin-like growth factor-1 on critical-size calvarial defects in Sprague-Dawley rats. Ann Plast Surg 1993; 31: 429-433.
68. Trippel SB. Potential role of insulinlike growth factors in fracture healing. Clin Orthop 1998; 355 (Suppl): S301-S313.
69. Boden SD et al. Lumbar spine fusion by local gene therapy with a cDNA encoding a novel osteoinductive protein (LMP-1). Spine 1998; 23: 2486-2492.
70. Linkhart TA, Mohan S, Baylink DJ. Growth factors for bone growth and repair: IGF, TGF beta and BMP. Bone 1996; 19: 1S-12S.
71. Azari K et al. Therapeutic potential of bone morphogenetic proteins. Expert Opin Investig Drugs 2001; 10: 1677-1686.
72. Alden TD et al. Bone morphogenetic protein gene therapy. Spine 2002; 27: S87-S93.
73. Yoon ST, Boden SD. Osteoinductive molecules in orthopaedics: basic science and preclinical studies. Clin Orthop 2002; 395: 33-43.
74. Solloway MJ et al. Mice lacking Bmp6 function. Dev Genet 1998; 22: 321-339.
75. Jane J et al. Ectopic osteogenesis using adenoviral bone morphogenetic protein (BMP)-4 and BMP-6 gene transfer. Mol Ther 2002; 6: 464.
76. Song JJ et al. Bone morphogenetic protein-9 binds to liver cells and stimulates proliferation. Endocrinology 1995; 136: 4293-4297.
77. Ploemacher RE et al. Bone morphogenetic protein 9 is a potent synergistic factor for murine hemopoietic progenitor cell generation and colony formation in serum-free cultures. Leukemia 1999; 13: 428-437.
78. Lopez-Coviella I et al. Induction and maintenance of the neuronal cholinergic phenotype in the central nervous system by BMP-9. Science 2000; 289: 313-316.
79. Dumont RJ et al. Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents. Neurosurgery 2002; 51: 1239-1245.
80. Peng Y et al. Transcriptional characterization of bone morphogenetic proteins (BMPs)-mediated osteogenic signaling. J Cell Biochem 2003; 90: 1149-1165.
81. He TC et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.